On April 9, 2018 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, reported that Geert Kersten, Chief Executive Officer, will present a corporate overview at The MicroCap Conference on Tuesday, April 10th at 10 a.m. Eastern time (Press release, Cel-Sci, APR 9, 2018, View Source [SID1234525236]). The conference will be held April 9-10, 2018 at the Essex House in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEL-SCI Corporation to present at The MicroCap Conference

About The MicroCap Conference

The MicroCap Conference is an exclusive event dedicated to connecting high-performing small and microcap companies with committed investors. It is an opportunity to be introduced to and speak with management at some of the most attractive companies, learn from various expert panels, and network with other small and microcap investors.

On April 9, 2018 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, reported that Nicolas Fellmann, CFO of Onxeo, will present and hold one-to-one meetings with investors at the H.C. Wainwright Annual Global Life Sciences Conference (Press release, Onxeo, APR 9, 2018, View Source [SID1234525237]). The conference is being held on April 8-10, 2018, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Onxeo corporate presentation – H.C. Wainwright Annual Global Life Sciences Conference:

Date: April 10, 2018

Time: 11:30-11:55 am CEST

Location: Salon Atlantique-Meridional (2nd floor); Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco

UPCOMING FINANCIAL PUBLICATIONS & EVENTS

Q1 2018 financial information: Friday, May 4, 2018, after market
Shareholder’s general meeting on the first call: Wednesday, May 16, 2018
Shareholder’s general meeting on the second call (if the required quorum was not reached at the first AGM): Tuesday, June 19, 2018

On April 6, 2018 NewLink Genetics Corporation (NASDAQ:NLNK) reported a review of its clinical programs (Press release, NewLink Genetics, APR 6, 2018, View Source [SID1234525805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This morning’s announcement by Incyte and Merck on the ECHO-301 trial for patients with advanced melanoma is a disappointing result for the IDO field. Indoximod, NewLink Genetics’ IDO pathway inhibitor, has a differentiated mechanism of action (MOA) which may demonstrate clinical benefit for patients where direct enzymatic inhibitors have not. In light of Incyte’s announcement, however, NewLink is undertaking a review of its clinical programs and will provide an update when it is completed.

NewLink Genetics has generated data for indoximod across several indications, and in combination with different modalities, suggesting the potential for indoximod to improve the outcomes for patients with cancer. The Company will present additional data at AACR (Free AACR Whitepaper) next week, including a poster presentation further supporting indoximod’s differentiated MOA and a plenary session presenting encouraging early clinical data of indoximod plus radiation for pediatric patients with diffuse intrinsic pontine glioma (DIPG), a rare and lethal form of brain cancer.

About Indoximod

Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, radiation, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.

(Filing, Annual, Celyad, 2017, APR 6, 2018, View Source [SID1234525205])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 6, 2018 AbbVie (NYSE: ABBV) reported its first-quarter 2018 financial results on Thursday, Apr. 26, 2018, before the market opens (Press release, AbbVie, APR 6, 2018, View Source [SID1234525199]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!